IRWD
Ironwood Pharmaceuticals Inc
$4.00
+0.02 (+0.50%)
At close · Jul 15
Market Cap
$658.45M
Shares
164,613,406
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$296.15M
-15.7%
FY2025
Net Income
$24.02M
+2629.2%
FY2025
Gross Margin
99.19%
+4.8pp
FY2020
Operating Margin
33.26%
+6.8pp
FY2025
Diluted EPS
$0.15
+1400%
FY2025
Operating Cash Flow
$127.04M
+22.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $450M – $475M | $361.51M | $296.15M | $351.41M | $442.74M | $410.6M | $413.75M | $389.52M | $428.41M | $346.64M | $298.28M | $273.96M | $149.56M | $76.44M | $22.88M | $150.25M | $65.87M | $43.86M | $34.32M | |
| — | — | — | — | — | — | — | $3.14M | $23.88M | $32.75M | $19.1M | $1.87M | $12K | $5.29M | $7.2M | $965K | — | — | — | |
| — | — | — | — | — | — | — | $386.39M | $404.54M | $313.89M | $279.18M | $272.09M | $149.54M | $71.15M | $15.68M | $149.28M | — | — | — | |
| — | — | — | — | — | — | — | 99.19% | 94.43% | 90.55% | 93.6% | 99.32% | 99.99% | 93.08% | 68.52% | 99.36% | — | — | — | |
| — | $89.64M | $95.14M | $111.42M | $116.09M | $44.27M | $70.41M | $88.06M | $115.04M | $101.06M | $88.15M | $139.49M | $108.75M | $101.89M | $102.38M | $113.47M | $86.09M | $77.45M | $76.1M | |
| — | $81.89M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $45.92M | $27.17M | $19.04M | |
| — | $70.03M | $82.26M | $144.27M | $158.31M | $115.99M | $111.13M | $140M | $172.45M | $219.68M | $231.18M | $173.28M | $125.25M | $118.33M | $123.23M | $92.54M | $45.92M | $27.17M | — | |
| — | — | — | — | — | — | — | — | — | $8.11M | $6.21M | $981K | — | — | — | — | — | — | — | |
| — | — | $1.1M | $1.2M | $1.2M | $1.4M | $1.5M | $2.3M | $5.6M | $3.9M | $6.4M | $10.28M | $11.63M | $12.33M | $11.73M | $11.33M | $10M | $6.16M | $4.76M | |
| — | — | $20.65M | $2.61M | $17.44M | — | $1.07M | $15.4M | $3.6M | $14.72M | — | — | — | $551K | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $132.01M | $104.62M | $95.14M | |
| — | $161.33M | $197.65M | $258.29M | $1.39B | $160.26M | $181.49M | $246.58M | $308.29M | $497.31M | $313.64M | $325.83M | $251.64M | $245.81M | $274.88M | $223.01M | $132.01M | $104.62M | — | |
| — | $200.18M | $98.5M | $93.12M | -$945.43M | $250.34M | $232.26M | $142.94M | $120.12M | -$150.67M | -$15.36M | -$51.87M | -$102.09M | -$169.37M | -$252M | -$72.76M | -$66.14M | -$60.77M | -$60.82M | |
| — | — | 33.26% | 26.5% | -213.54% | 60.97% | 56.13% | 36.7% | 28.04% | -43.47% | -5.15% | -18.93% | -68.26% | -221.58% | -1101.36% | -48.43% | -100.41% | -138.55% | -177.2% | |
| — | — | $99.6M | $94.32M | -$944.23M | $251.74M | $233.76M | $145.24M | $125.72M | -$146.77M | -$8.96M | -$41.59M | -$90.46M | -$157.04M | -$240.27M | -$61.44M | -$56.14M | -$54.61M | -$56.05M | |
| — | $33.82M | $32.75M | $33.03M | $21.63M | $7.6M | $31.15M | $29.48M | $36.6M | $37.72M | $36.37M | $39.15M | $31.1M | $21.17M | $21M | $59K | $63K | $196K | $318K | |
| — | -$28.71M | -$28.48M | -$27.93M | -$2.64M | $2.09M | -$31.6M | -$34.08M | -$61.18M | -$43.48M | -$39.55M | -$29.84M | -$40.58M | -$20.25M | -$20.81M | $138K | $1.29M | $1.41M | $522K | |
| — | $171.47M | $70.03M | $65.2M | -$948.07M | $252.42M | $200.66M | $108.86M | $58.94M | -$194.15M | — | — | — | — | -$272.81M | -$72.62M | -$64.85M | -$59.36M | -$60.29M | |
| — | $69.29M | $46.01M | $64.32M | $83.49M | $77.36M | -$327.79M | $2.69M | $0 | $0 | $0 | $0 | $0 | $0 | — | — | $3000 | -$2.94M | -$296K | |
| — | $102.18M | $24.02M | $880K | -$1B | $175.07M | $528.45M | $106.18M | $21.51M | -$282.37M | -$116.94M | -$81.71M | -$142.67M | — | — | -$72.62M | -$64.85M | -$51.86M | -$73.31M | |
| — | — | 8.11% | 0.25% | -226.37% | 42.64% | 127.72% | 27.26% | 5.02% | -81.46% | -39.2% | -29.83% | -95.4% | — | — | -48.34% | -98.45% | -118.25% | -213.61% | |
| — | — | — | — | -$29.32M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $102.18M | $24.02M | $880K | -$1B | $175.07M | $528.45M | $106.18M | $21.51M | -$282.37M | — | -$81.71M | -$142.67M | -$189.62M | -$272.81M | -$72.62M | -$64.85M | -$52.98M | -$71.19M | |
| — | $101.09M | $22.03M | $4.83M | -$1.01B | $175.07M | $528.45M | $106.18M | $21.51M | -$282.29M | -$117.01M | -$81.63M | -$142.74M | -$189.64M | -$272.82M | -$72.63M | -$64.85M | -$52.98M | — | |
| USD/shares | — | — | $0.15 | $0.01 | -$6.45 | $1.13 | $3.26 | $0.67 | $0.14 | -$1.85 | — | — | — | — | -$2.35 | -$0.68 | -$0.65 | — | — |
| USD/shares | — | — | $0.15 | $0.01 | -$6.45 | $0.96 | $3.21 | $0.66 | $0.14 | -$1.85 | — | — | — | — | -$2.35 | -$0.68 | -$0.65 | — | — |
| shares | — | — | 161.84M | 159.08M | 155.44M | 154.37M | 162.25M | 159.43M | 156.02M | 152.63M | 148.99M | 144.93M | 142.16M | 136.81M | 115.85M | 106.4M | 99.87M | 89.65M | 7.12M |
| shares | — | — | 162.98M | 160.08M | 155.44M | 186.31M | 164.42M | 160.66M | 156.02M | 152.63M | 148.99M | 144.93M | 142.16M | 136.81M | 115.85M | 106.4M | 99.87M | 89.65M | 7.12M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2021–FY2022: $150.53M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Drug Manufacturers - Specialty & Generic median 2.11×
EV/EBIT
—
Drug Manufacturers - Specialty & Generic median 34.24×
P/E (TTM)
6.67×
Drug Manufacturers - Specialty & Generic median 21.04×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Collaborative Arrangements | $296,151,000 | $351,410,000 | $442,735,000 | $410,596,000 | $412,784,000 | $381,545,000 | $379,652,000 | $272,839,000 |
| Collaborative Arrangement Other Agreements | $87,000 | $734,000 | $2,476,000 | $1,824,000 | $1,755,000 | $1,335,000 | $1,845,000 | $1,226,000 |
| Active Pharmaceutical Ingredient | — | — | — | — | $969,000 | $7,978,000 | $48,761,000 | $70,355,000 |
| Product | — | — | — | — | — | — | — | $3,445,000 |
Key facts
CIK
1446847
CUSIP
46333X108
13F (30d)
12 filings
12 filers
Visit website
Investor relations